

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Drysdale, Connie M.; Judson, Richard S.; Liggett, Stephen B.;
Nandabalan, Krishnan; and Stephens, J. Claiborne.

Application No.: To be assigned
Filed: March 16, 2001

Group No.: To be assigned
Examiner: To be assigned

For: ASSOCIATION OF BETA2-ADRENERGIC RECEPTOR HAPLOTYPES WITH DRUG
RESPONSE

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT TO CLAIMS
(37 C.F.R. 1.121 and M.P.E.P. 714.09)

This application is a continuation of pending PCT application PCT/US00/10125. Prior to calculating the filing fee, it is respectfully requested that the claims be amended as indicated below.

IN THE CLAIMS

Please cancel claims 9-12 and 21-24 without prejudice or disclaimer

REMARKS

Upon entry of this amendment, claims 1-8, 13-20, and 25-29 are pending. This amendment cancels claims that are being pursued in a separate continuation application of PCT/US00/10125 filed concurrently herewith. Should any questions arise, or if Applicants or Applicants' Attorney can facilitate examination of this Application, please contact the undersigned Attorney at the phone number below.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Drysdale, Connie M.; Judson, Richard S.; Liggett, Stephen B.;
Nandabalan, Krishnan; and Stephens, J. Claiborne.

Application No.: To be assigned
Filed: March 16, 2001

Group No.: To be assigned
Examiner: To be assigned

For: ASSOCIATION OF BETA2-ADRENERGIC RECEPTOR HAPLOTYPES WITH DRUG
RESPONSE

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT TO CLAIMS
(37 C.F.R. 1.121 and M.P.E.P. 714.09)

This application is a continuation of pending PCT application PCT/US00/10125. Prior to calculating the filing fee, it is respectfully requested that the claims be amended as indicated below.

IN THE CLAIMS

Please cancel claims 9-12 and 21-24 without prejudice or disclaimer

REMARKS

Upon entry of this amendment, claims 1-8, 13-20, and 25-29 are pending. This amendment cancels claims that are being pursued in a separate continuation application of PCT/US00/10125 filed concurrently herewith. Should any questions arise, or if Applicants or Applicants' Attorney can facilitate examination of this Application, please contact the undersigned Attorney at the phone number below.